Rapha, Leticia e Lucca discutem 7 armadilhas na doença do refluxo gastroesofageana (DRGE)! Referências: -Fass, Ronnie. “Gastroesophageal Reflux Disease.” The New England journal of medicine vol. 387,13 (2022): 1207-1216. doi:10.1056/NEJMcp2114026 -Parmar, Malvinder S. “Gastroesophageal Reflux Disease.” The New England journal of medicine vol. 388,9 (2023): 863. doi:10.1056/NEJMc2213991 -Jenkins, Danny, and Ines Modolell. “Proton pump inhibitors.” BMJ (Clinical research ed.) vol. 383 e070752. 13 Nov. 2023, doi:10.1136/bmj-2022-070752 -Katzka, David A, and Peter J Kahrilas. “Advances in the diagnosis and management of gastroesophageal reflux disease.” BMJ (Clinical research ed.) vol. 371 m3786. 23 Nov. 2020, doi:10.1136/bmj.m3786 -Barr J, Gulrajani NB, Hurst A, Pappas TN. Bottoms Up: A History of Rectal Nutrition From 1870 to 1920. Ann Surg Open. 2021;2(1):e039. Published 2021 Feb 10. doi:10.1097/AS9.0000000000000039 -Fass, R et al. “Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.” Alimentary pharmacology & therapeutics vol. 29,12 (2009): 1261-72. doi:10.1111/j.1365-2036.2009.04013.x -Lee, R D et al. “Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.” Alimentary pharmacology & therapeutics vol. 29,8 (2009): 824-33. doi:10.1111/j.1365-2036.2009.03979.x -Metz, D C et al. “Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.” Alimentary pharmacology & therapeutics vol. 29,7 (2009): 742-54. doi:10.1111/j.1365-2036.2009.03954.x -Ip, Stanley, et al. Comparative Effectiveness of Management Strategies For Gastroesophageal Reflux Disease. Agency for Healthcare Research and Quality (US), December 2005. -https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020839s078lbl.pdf -Zhuang, Qianjun et al. “Comparative efficacy of P-CABs versus proton pump inhibitors for Grade C/D esophagitis: A systematic review and network meta-analysis.” The American journal of gastroenterology, 10.14309/ajg.0000000000002714. 12 Feb. 2024, doi:10.14309/ajg.0000000000002714 -Iwakiri K, Fujiwara Y, Manabe N, Ihara E, Kuribayashi S, Akiyama J, Kondo T, Yamashita H, Ishimura N, Kitasako Y, Iijima K, Koike T, Omura N, Nomura T, Kawamura O, Ohara S, Ozawa S, Kinoshita Y, Mochida S, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022 Apr;57(4):267-285. doi: 10.1007/s00535-022-01861-z. Epub 2022 Feb 28. PMID: 35226174; PMCID: PMC8938399. -Graham, David Y, and Aylin Tansel. “Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. 16,6 (2018): 800-808.e7. doi:10.1016/j.cgh.2017.09.033 -Hatlebakk, J G et al. “Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily.” Alimentary pharmacology & therapeutics vol. 12,12 (1998): 1235-40. doi:10.1046/j.1365-2036.1998.00426.x -Chen JW, Vela MF, Peterson KA, Carlson DA. AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease: Expert Review. Clin Gastroenterol Hepatol. 2023 Jun;21(6):1414-1421.e3. doi: 10.1016/j.cgh.2023.01.040. Epub 2023 Apr 14. PMID: 37061897. -Gyawali CP, Yadlapati R, Fass R, Katzka D, Pandolfino J, Savarino E, Sifrim D, Spechler S, Zerbib F, Fox MR, Bhatia S, de Bortoli N, Cho YK, Cisternas D, Chen CL, Cock C, Hani A, Remes Troche JM, Xiao Y, Vaezi MF, Roman S. Updates to the modern diagnosis of GERD: Lyon consensus 2.0. Gut. 2024 Jan 5;73(2):361-371. doi: 10.1136/gutjnl-2023-330616. PMID: 37734911; PMCID: PMC10846564. -Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022 Jan 1;117(1):27-56. doi: 10.14309/ajg.0000000000001538. PMID: 34807007; PMCID: PMC8754510. -Hicks DM, Ours TM, Abelson TI, et al. The prevalence of hypopharynx findings associated with gastroesophageal reflux in normal volunteers. J Voice 2002;16(4):564–79. -Blondeau K, Dupont LJ, Mertens V, et al. Improved diagnosis of gastro-oesophageal reflux in patients with unexplained chronic cough. Aliment Pharmacol Ther 2007;25:723–732.